1 To further understand what factors might influence whether patients were likely to maintain, regain, or lose more weight, we studied 25,552 patients prescribed semaglutide and 33,456 patients prescribed liraglutide for at least 90 days continuously between January 1, 2017, and February 1, 2023
Instead, they target the receptors responsible for the physiological processes of growth hormone release
Multiple studies have confirmed that six drugs, including liraglutide and semaglutide, have all demonstrated significant dose-dependent weight loss effects [59]
In 2026, less than 1% of Part D enrollees are in a drug plan that covers Wegovy, the GLP-1 covered by Medicare for cardiovascular disease